Disruption of the brain’s hunger and satiety control mechanisms can lead to rapid weight gain that is difficult to treat with conventional dietary interventions because patients do not experience an adequate sense of fullness.

Speaking at a joint press conference hosted by the German Diabetes Society and the German Society of Endocrinology, Ulrich Dischinger, MD, senior physician in the Department of Endocrinology and Diabetology at the University Hospital of Würzburg in Würzburg, Germany, emphasized that hypothalamic obesity is a distinct clinical condition that remains underrecognized.

“Hypothalamic obesity clearly demonstrates that body weight is not primarily determined by willpower or lifestyle but depends heavily on central nervous system regulatory circuits,” said Dischinger.

Dischinger emphasized that this distinction is important because hypothalamic obesity, like common obesity, is frequently misclassified as a lifestyle-related condition.

Rapid Weight Gain

If the hypothalamus, the brain’s central regulatory center, is damaged by a tumor (such as a craniopharyngioma), surgery, trauma, or an inflammatory process, the body’s energy regulation system can become permanently disrupted, as explained by Dischinger. The result is often hypothalamic obesity, which is a form of obesity that is difficult to treat. Clinically, the condition typically presents with rapid, sometimes substantial, weight gain. Many patients also develop excessive hunger and experience little or no sense of satiety.

“When patients experience rapid weight gain after hypothalamic damage and report little or no sense of satiety, hypothalamic obesity should be considered as part of a complex hypothalamic syndrome,” Dischinger said. He added that the temporal relationship between hypothalamic injury, weight gain, and hyperphagia is a key diagnostic criterion.

Eating Behavior

Eating patterns may also provide important diagnostic clues. According to Dischinger, many patients exhibit craving-like eating behaviors and may wake during the night to eat. Under normal physiologic conditions, hunger does not typically disrupt sleep. Body temperature may also provide diagnostic insights because patients with hypothalamic obesity often have lower body temperature resulting from hypothalamic dysfunction.

According to Dischinger, traditional dietary and behavioral interventions are often only moderately effective because the underlying problem lies in impaired central regulation rather than behavior alone. Neurons in the arcuate nucleus of the hypothalamus, particularly pro-opiomelanocortin (POMC) neurons and agouti-related peptide/neuropeptide Y (AgRP/NPY) neurons, play a central role in regulating food intake. These neurons exert their physiologic effects through the melanocortin 4 receptor (MC4R).

Appetite Balance

POMC neurons release anorexigenic (appetite-suppressing) signals. Conversely, AgRP/NPY neurons promote hunger by expressing orexigenic peptides and have appetite-stimulating effects.

Hypothalamic damage disrupts this balance, often shifting signaling toward orexigenic pathways. As a result, patients may experience persistent hunger regardless of the body’s actual energy reserves.

Dischinger noted that previous treatment with medications such as metformin and dextroamphetamine has generally produced limited benefits. However, GLP-1 receptor agonists can be effective in patients with hypothalamic obesity. Because their efficacy depends, in part, on the intact central regulation of hunger and satiety, treatment responses vary among patients.

The same applies to bariatric surgery. Dischinger and colleagues found that its effectiveness depends on an intact hypothalamus. Although participants with hypothalamic damage had higher postoperative hormone concentrations than those with an intact hypothalamus, they experienced substantially less weight loss after surgery.

These findings suggest that the benefits of bariatric surgery depend largely on neuroendocrine signals originating in the gastrointestinal tract and on an intact hypothalamus.

New Therapy

Setmelanotide, a selective MC4R agonist, is a new treatment option. The drug specifically targets the melanocortin signaling pathway and can partially compensate for impaired satiety signaling. Originally approved for rare genetic forms of obesity, it is now indicated for the treatment of hypothalamic obesity. However, clinical data supporting its use in this population remain limited.

Dischinger believed that many cases of hypothalamic obesity remain undiagnosed.

“It is likely that many patients with hypothalamic obesity are not correctly diagnosed,” Dischinger said. He added that the persistent perception of obesity as a condition caused solely by diet and lifestyle likely contributes to the underrecognition of the disorder.

Multimodal Care

Because hypothalamic obesity is a complex disorder, its management requires a multimodal approach incorporating endocrinologic, nutritional, and, when a tumor is the underlying cause, neuro-oncologic care. Dischinger emphasized that treating hypothalamic obesity requires considerable clinical expertise. Clinicians should consider therapies that have shown benefits in alimentary obesity, while recognizing that treatment often requires an individualized approach.

“When in doubt, one should proceed according to the trial-and-error principle,” Dischinger said.

He also noted that other features of hypothalamic syndrome, including sleep disturbances and temperature dysregulation, should be addressed as part of the overall treatment strategy. However, because hypothalamic obesity is still often viewed as a lifestyle-related condition, pharmacologic treatment is generally not covered by insurance, Dischinger concluded.

This story was translated from Medscape’s German edition.